Oslo Myeloma Center

The trials here

What the 2 trials at this site are about, from their registry records.

Conditions

• Multiple myeloma2 trials

Phase

• Phase 1/21 trial
• Phase 21 trial

Status

• Active, not recruiting1 trial
• Recruiting1 trial

Lead sponsor

• European Myeloma Network B.V.1 trial
• Oslo University Hospital1 trial

Running trials

• Active, not recruiting

  Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma

  NCT06183489· Phase 2· European Myeloma Network B.V.· Source

• Recruiting

  The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma

  NCT05841550· Phase 1/2· Oslo University Hospital· Source

  Contact: Fredrik B Schjesvold, MD, PhD

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Multiple myeloma1 recruiting